Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07579910
PHASE3
Intracerebroventricular Tralesinidase Alfa in Children With Mucopolysaccharidosis Type IIIB
Sponsor: Spruce Biosciences
View on ClinicalTrials.gov
Summary
The primary objectives of this study are to evaluate the effects of Tralesinidase Alfa (TA) on cognition
Official title: A Phase 3, Randomized, Single-blind, Parallel Group, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebroventricular Tralesinidase Alfa Treatment Compared to Standard of Care in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)
Key Details
Gender
All
Age Range
1 Year - 5 Years
Study Type
INTERVENTIONAL
Enrollment
14
Start Date
2026-12
Completion Date
2033-08
Last Updated
2026-05-12
Healthy Volunteers
No
Conditions
Interventions
DRUG
Tralesinidase alfa (TA)
TA study drug is a sterile solution for ICV infusion.